Quest Diagnostics aims to replace PET-CT scans using FDA-cleared blood tests for Alzheimer's disease.
2 reports, 1 independent
Updated Jul 15
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Quest Diagnostics aims to replace PET-CT scans using FDA-cleared blood tests for Alzheimer's disease.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Quest Diagnostics
medical research company
- FDA
Related events
Coverage
Newest first; wire copies grouped- MedTech DiveQuest to offer Fujirebio’s FDA-cleared Alzheimer’s blood test This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newslet
- Unknown outlet